Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
- Figures corrected afterwards (2022).
Gross margin
€ -3.3 million
▼ 65% vs 2024
Profit
Caution€ -3.6 million
▼ 70% vs 2024
Debts
High€ 3.3 million
▲ 987% vs 2024
DeuterOncology from Liège, company number BE0754971388, closed financial year 2025 with a result of € -3.6 million after tax. For that financial year DeuterOncology recorded a gross margin of € -3.3 million and equity of € -2.6 million. Compared with financial year 2024, the result moved from € -2.1 million to € -3.6 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
What happened at DeuterOncology?
What happened at DeuterOncology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Newton Biocapital Partners SRL stepped down as director. NBB
- NOSHAQ PARTNERS SRL stepped down as director. NBB
- Iker Huerga stepped down as director. NBB
- Alexander Patrick Dolan stepped down as director. NBB
- Kipp Richard Fairchild Davis stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 3.6 million. Source: NBB ↗
- Iker Huerga became a director. NBB
- Alexander Patrick Dolan became a director. NBB
In short
From € 1.1 million loss in 2021 to € 3.6 million loss in 2025.
A new publication or filing at DeuterOncology? We notify you, reason included.
Follow DeuterOncologyNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Newton Biocapital Partners SRL
Director · represented by Pierre DETRIXHE
Also active at: SYNERGIA MEDICAL, Newton Biocapital I, pricaf privée de droit belge, Newton Biocapital I Investment Pool +4 more
since 2021 · until 2032
Director · represented by Hélène SABATEL
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2022 · until 2032
Iker Huerga
Director
since 2026 · until 2032
Alexander Patrick Dolan
Director
since 2026 · until 2032
Kipp Richard Fairchild Davis
Director
since 2026 · until 2032
Establishments
Establishment units
Physical locations of this company
Clos Chanmurly 13
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 36 companies are registered at this address.
AASA Architectes
€ 155,212 gross margin · 2025
1Spatial Belgium
€ 2.7 million revenue · 2025
ICÔN INTERNATIONAL BENELUX
€ 185,639 gross margin · 2024
GESCOM
TECHNIQUES GENERALES ET INFRASTRUCTURES
€ 528,630 gross margin · 2025
+31 more
Details
- Company number
- 0754.971.388
- VAT number
- BE 0754.971.388
- Registered office
- Clos Chanmurly 13, 4000 Liège
- Names & denominations
- DeuterOncology
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 September 2020
- Peppol
- Active · Active since 10 Mar 2026
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied